Humacyte, Inc. is engaged in the development and manufacturing of off-the-shelf, universally implantable, bioengineered human tissues. Co. is engaged in developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction, and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). Co. has developed a novel paradigm for manufacturing human tissues that are intended to mimic key aspects of human physiology. The HUMA average annual return since 2020 is shown above.
The Average Annual Return on the HUMA average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether HUMA average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the HUMA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|